BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Feb. 25, 2004
View Archived Issues
InDex Signs $35M Agreement With Serono For Inflammation
InDex Pharmaceuticals AB signed its first product deal, out-licensing its antisense drug Kappaproct to Serono SA, of Geneva, for treatment of ulcerative colitis and other inflammatory conditions. (BioWorld International)
Read More
Domantis Plans dAbs Trials With £17.5M In Second-Round Funds
Read More
Targeted Cancer Therapy Might Enter Clinical Trials Later In 2004
Read More
Borean Pharma Brings In ApoA-I Project Via Proteopharma Buyout
Read More
University Of Glasgow, Pharmetix Join Together To Start Grannus
Read More
EU Biotech Firms Worry New Rules Will Hinder Deal-Making
Read More
Graffinity Raises EUR15M In Third Round For Discovery Programs
Read More
Other News To Note
Read More